Eli Lilly announced a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, to produce its next‑generation obesity injectables, including retatrutide, and related devices. The plant is intended to secure supply for anticipated high demand in weight‑management therapies and to support device integration at commercial scale. Lilly positioned the investment as part of an industrial build‑out to meet global demand for GLP‑1 and next‑generation peptide drugs. The new factory will increase capacity for injectable and device assembly and reduce supply chain risk for high‑volume obesity drugs. The move underlines how leading pharma companies are vertically scaling production to control launch economics and speed to market for high‑value metabolic categories.